Warning Vanda Pharmaceuticals Inc. (VNDA) optimists! Richard Gulino just Unloaded 3,660 shares.; Energen Has 1.02 Sentiment

Energen Corporation, through its subsidiary, Energen Resources Corporation, engages in the exploration, development, and production of oil, natural gas liquids, and natural gas. The company has market cap of $5.42 billion. It has activities within the Midland Basin, the Delaware Basin, and the Central Basin Platform areas of the Permian Basin in west Texas and New Mexico. It has a 17.77 P/E ratio.

Recently, an insider trading transaction was made. Richard Gulino, the SVP – General Counsel & Sec. and an insider of Vanda Pharmaceuticals Inc sold a total of 3,660 shares of Vanda Pharmaceuticals Inc, worth approx. $68,473 U.S Dollars, at $18.7 for each share at the time of the transaction. The dated March 2, 2018 transaction’s filing which was filed with the (SEC) is ready for you here. Richard Gulino now has 115,073 shares of the Firm.

Among 8 analysts covering Vanda Pharmaceuticals (NASDAQ:VNDA), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vanda Pharmaceuticals has $26.0 highest and $15 lowest target. $22.25’s average target is 17.11% above currents $19 stock price. Vanda Pharmaceuticals had 23 analyst reports since September 2, 2015 according to SRatingsIntel. The stock has “Market Outperform” rating by JMP Securities on Friday, August 26. The stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has “Outperform” rating given on Monday, October 30 by Oppenheimer. As per Wednesday, March 9, the company rating was maintained by JMP Securities. The firm earned “Buy” rating on Wednesday, November 9 by Aegis Capital. The company was initiated on Wednesday, October 21 by Brean Capital. The stock has “Buy” rating by Piper Jaffray on Thursday, August 3. Piper Jaffray maintained Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) rating on Thursday, October 19. Piper Jaffray has “Buy” rating and $26.0 target. As per Wednesday, February 28, the company rating was maintained by Seaport Global. Oppenheimer maintained the shares of VNDA in report on Thursday, August 3 with “Buy” rating. Piper Jaffray initiated Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) rating on Tuesday, June 27. Piper Jaffray has “Buy” rating and $2300 target.

Analysts await Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to report earnings on May, 1. They expect $-0.14 earnings per share, up 17.65% or $0.03 from last year’s $-0.17 per share. After $-0.04 actual earnings per share reported by Vanda Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts 250.00% negative EPS growth.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company has market cap of $863.32 million. The company??s marketed products include HETLIOZ , a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt (iloperidone), a product for the treatment of schizophrenia. It currently has negative earnings. The Company’s clinical development products include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; Trichostatin A, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.

Investors sentiment increased to 1.43 in Q3 2017. Its up 0.26, from 1.17 in 2017Q2. It improved, as 12 investors sold Vanda Pharmaceuticals Inc. shares while 34 reduced holdings. 21 funds opened positions while 45 raised stakes. 38.89 million shares or 4.39% more from 37.25 million shares in 2017Q2 were reported. First Trust Limited Partnership has invested 0% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). 591,786 were accumulated by Northern Tru. Citigroup reported 128,053 shares. Renaissance Techs Limited Co holds 1.22 million shares or 0.03% of its portfolio. 464 are owned by Tower Capital Ltd Llc (Trc). Clarivest Asset Management Limited Co stated it has 5,999 shares. Delaware-based Dupont Cap Mngmt has invested 0.03% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Ajo L P invested in 0.04% or 503,255 shares. Moreover, Cadence Mgmt Ltd Liability has 0.07% invested in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) for 62,606 shares. Bogle Inv Mngmt Lp De stated it has 352,604 shares. 65,600 are held by Hbk Limited Partnership. Rothschild Asset Mngmt Inc, New York-based fund reported 1.31M shares. Panagora Asset Management reported 0.02% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Moreover, Ameriprise has 0% invested in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) for 88,160 shares. Sei Investments Com stated it has 0.02% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA).

The stock increased 1.60% or $0.3 during the last trading session, reaching $19. About 590,565 shares traded or 0.72% up from the average. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has risen 51.60% since March 3, 2017 and is uptrending. It has outperformed by 34.90% the S&P500.

Since January 2, 2018, it had 0 buys, and 4 sales for $3.36 million activity. Polymeropoulos Mihael Hristos had sold 191,760 shares worth $2.93 million. Another trade for 10,367 shares valued at $157,565 was sold by Gulino Richard L. $130,777 worth of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) was sold by Birznieks Gunther. Another trade for 9,155 shares valued at $140,494 was sold by Kelly James Patrick.

The stock increased 1.68% or $0.92 during the last trading session, reaching $55.79. About 664,662 shares traded. Energen Corporation (EGN) has risen 35.21% since March 3, 2017 and is uptrending. It has outperformed by 18.51% the S&P500.

Corvex Management Lp holds 20.13% of its portfolio in Energen Corporation for 9.79 million shares. Brenham Capital Management L.P. owns 1.80 million shares or 13.47% of their US portfolio. Moreover, Cambrian Capital Limited Partnership has 5.76% invested in the company for 86,576 shares. The Texas-based Mitchell Group Inc has invested 3.25% in the stock. Systematic Financial Management Lp, a New Jersey-based fund reported 1.31 million shares.